|
Neurodegenerative Disorders
|
0.400 |
Therapeutic
|
group |
CTD_human |
Thus, SIRT1 constitutes a unique molecular link between aging and human neurodegenerative disorders and provides a promising avenue for therapeutic intervention.
|
17581637 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
LHGDN |
Thus, SIRT1 constitutes a unique molecular link between aging and human neurodegenerative disorders and provides a promising avenue for therapeutic intervention.
|
17581637 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Thus, SIRT1 constitutes a unique molecular link between aging and human neurodegenerative disorders and provides a promising avenue for therapeutic intervention.
|
17581637 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Therapeutic
|
group |
CTD_human |
SIRT1 activation confers neuroprotection in experimental optic neuritis.
|
17652729 |
2007 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Presently, SIRT1 is gaining increasing importance in the development of innovative treatment strategies for cancer, neurodegenerative disorders and metabolic disease.
|
18774777 |
2008 |
|
Neurodegenerative Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Perplexingly, manipulations that either increase or decrease Sirt1 activity have both been associated with a beneficial effect in animal models of ageing-associated disorders, such as neurodegenerative diseases.
|
19912989 |
2010 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In this review, we summarize the in vitro, in vivo, and genetic experimental results linking SIRT1 and the other sirtuins to AD, while a description of sirtuins' biochemical features and modulating compounds, as well as sirtuins' involvement in other neurodegenerative disorders are discussed as collateral aims.
|
20061622 |
2010 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
SIRT1 gene has been connected to many cellular processes and implicated in human diseases, such as obesity, type 2 diabetes, cancer and neurodegenerative diseases.
|
22613205 |
2012 |
|
Neurodegenerative Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Sirtuins (SIRT1-7; class III histone deactylases) modulate fundamental mechanisms in age-related neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
|
22796962 |
2013 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
SIRT1 has been involved in many cellular processes and implicated in human diseases, such as obesity, type 2 diabetes, cancer and neurodegenerative diseases.
|
22885181 |
2012 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
During the past decade, investigators have reported the relationship between disturbance of Sirt1 activation and the onset of aging- and obesity-associated diseases such as diabetes, cardiovascular disease and neurodegenerative disorders.
|
23361587 |
2013 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We discuss different functions and targets of SIRT1 and SIRT2 in a variety of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's Disease (HD).
|
23417962 |
2013 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Sirtuins (SIRT1-7) are NAD(+)-dependent histone deacetylases (HDACs) that play an important role in the control of metabolism and proliferation and the development of age-associated diseases like oncologic, cardiovascular and neurodegenerative diseases.
|
23499872 |
2013 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
During the past decade, sirtuin-1 (SIRT1) has been the focus of intense investigation and discussion because it regulates longevity in multiple organisms and has shown beneficial effects in a variety of models of neurodegenerative disorders.
|
23549885 |
2013 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Resveratrol is a putative SIRT1 activator that has been shown to delay neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Alzheimer, and Huntington's disease.
|
24252177 |
2014 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Sirt1 serves as a deacetylase for numerous proteins involved in several cellular pathways, including stress response and apoptosis, and plays a protective role in neurodegenerative disorders, such as AD.
|
24496572 |
2014 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, SIRT1 plays protective roles in several neurodegenerative diseases including Alzheimer's, Parkinson's, and motor neuron diseases, which may relate to its functions in metabolism, stress resistance, and genomic stability.
|
24507186 |
2014 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
We have then focused on class III histone deacetylases SIRT1 and SIRT2 that are considered relevant in neurodegenerative diseases.
|
24946089 |
2014 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
SIRT1 plays a key role in the pathophysiology of metabolic diseases and neurodegenerative disorders, and is considered to protect against age-related diseases including cancer.
|
26862948 |
2017 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Both activation and inhibition of SIRT1 were previously shown to ameliorate neuropathological mechanisms in Huntington's disease (HD), a neurodegenerative disease that selectively affects the striatum and cortex and is commonly linked to mitochondrial dysfunction.
|
27590140 |
2017 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Silent information regulator family protein 1 (SIRT1), a member of the NAD<sup>+</sup>-dependent protein deacetylases, has been shown to exhibit neuroprotective activities in animal models of various pathologies, including ischemic brain injury, subarachnoid hemorrhage and several neurodegenerative diseases.
|
28017962 |
2017 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Since the first pan-HDAC inhibitor SAHA was approved by U.S. FDA 10 years ago, HDACs including SIRT1-7 have received significant attention due to the fact that aberrant histone deacetylase activtiy has been implicated in a variety of human diseases, such as cancers, virus infection, and neurodegenerative diseases.
|
28033734 |
2017 |
|
Neurodegenerative Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders.
|
28086917 |
2017 |
|
Neurodegenerative Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Both the silent mating type information (Sirt1) expression and mitogen-activated protein kinase (MAPK) signal pathway activation represent a promising therapeutic target for several models of neurodegenerative diseases.
|
28356158 |
2017 |
|
Neurodegenerative Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These findings suggests a negative effect of oxidative stress in neurodegenerative disorders and possibly explain the reduced activity of SIRT1 in neurodegenerative disorders.
|
28578695 |
2017 |